Tag: Zhong Lun
Research, recalibrate, repeat
Market shakeups lead to increasingly complex dispute issues and novel investor strategies to resolve them
Firms guide HEC Technology’s RMB28bn WinTriX acquisition
Jia Yuan, Zhong Lun, KWM and Haiwen advise on HEC’s RMB28b acquisition of WinTrix DC, China’s biggest data centre M&A
Mapping a path through M&A law
M&A key updates from Taiwan, India, Japan, South Korea, China and Thailand
Han Kun, Zhong Lun act on Sino Biopharm’s USD950m LaNova buy
Han Kun and Zhong Lun advised on Sino Biopharm’s USD950m acquisition of cancer drugmaker LaNova Medicines
Firms aid home appliance giant Haier’s RMB2.5bn acquisition
Zhong Lun, Clifford Chance, Grandway advise Haier on RMB2.5bn acquisition of controlling stake in Step Electric
Firms act on Kelun-Biotech’s HKD1.9bn H-share placement
Zhong Lun, S&C, Kirkland & Ellis advised on Kelun-Biotech’s HKEX H-share placement raising HKD1.94b (USD250m)
Insolvency: from crisis to reform
China’s slowing economy highlights insolvency challenges, including outdated laws, cross-border issues, and resistance to change
Quartet advises Mixue’s HKD3.46bn IPO on HKEX
Mixue Group raised HKD3.46 billion in its HKEX debut
Resolving the blame game
China’s recent surge of equity-related disputes reflects testing economic times – and the importance of swift, effective resolution
Quintet assists on CR Beverage’s HKD5bn listing
Clifford Chance, Jingtian & Gongcheng, Harneys, Paul Hastings, and Zhong Lun advised on China Resources Beverage’s HKD5bn HKEX debut
Proceed with caution
China's capital market faces tighter regulation, fewer new listings, and renewed interest in key international markets
Seven firms assist on first humanoid robot maker’s HK listing
Ashurst, King & Wood Mallesons, Bird & Bird, Guangdong Sun Law Firm, Deacons, Dorsey and Zhong Lun Law Firm have advised on Chinese robot maker UBTech Robotics’ IPO
Cancer drug firm Adlai Nortye raises USD97.5m in Nasdaq IPO
O’Melveny, Han Kun Law Offices, Maples Group, Latham & Watkins and Zhong Lun Law Firm advised on cancer drug developer Adlai Nortye’s Nasdaq debut
Smart moves
With businesses besieged on multiple fronts, Chinese and international law firms offer tips for survival
